HLA antibodies can lead to patients becoming refractory to platelet transfusions, and transfusions can be difficult when HLA-matched donors cannot be found. Only a few case reports have examined denaturing HLA Class I antigens from platelets before transfusion, and the transfusion outcomes have been variable. Results from a new study published in TRANSFUSION suggest that acid treatment removes 70-90% of the Class I HLA complexes. These platelets remain viable, aggregate normally, respond normally to natural agonists, and protect platelets from HLA-antibody-mediated complement lysis and monocyte-mediated phagocytosis in vitro. The results suggest that acid-treated platelets may be an alternative to HLA-matched platelets in refractory patients. The immunogenicity and refractoriness of acid-treated platelets, however, requires further study.
Reference
Transfusion offers CME credit for this study! Log on at www.wileyhealthlearning.com/trf.